June 17 (Reuters) - Verve Therapeutics Inc VERV.O:
LILLY TO ACQUIRE VERVE THERAPEUTICS TO ADVANCE ONE-TIME TREATMENTS FOR PEOPLE WITH HIGH CARDIOVASCULAR RISK
ELI LILLY - PROPOSED DEAL FOR PURCHASE PRICE OF $10.50 PER SHARE IN CASH
ELI LILLY - PROPOSED DEAL FOR A TOTAL POTENTIAL CONSIDERATION OF UP TO $13.50 PER SHARE IN CASH WITHOUT INTEREST
ELI LILLY - TRANSACTION IS NOT SUBJECT TO ANY FINANCING CONDITION
ELI LILLY: CVR HOLDERS WOULD BE ENTITLED TO GET CONTINGENT PAYMENT UPON FIRST PATIENT BEING DOSED WITH VERVE-102 FOR ASCVD IN U.S. PHASE 3 TRIAL
Source text: ID:nPn5VQH2Fa
Further company coverage: VERV.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.